Eisai, Merck & Co.’s Lenvima Patent Clashes Down to Validity

Eisai Co. Ltd. and Merck & Co.’s battle with Shilpa Medicare Ltd. over a generic version of the blockbuster Lenvima is down to validity after Shilpa conceded its proposed copy infringes two patents for the cancer drug’s manufacturing process.

Shilpa has argued its proposed generic Lenvima “contains a salt of Lenvatinib that is prepared by a process that is distinguishable from the process disclosed” in the patents, which the plaintiffs have disputed. But Shilpa agreed its copy infringes the patents so the parties can “conserve resources and narrow the triable issues,” according to a proposed stipulation and order filed Wednesday ...